Senate holds hearing on anticompetitive drugmaker conduct

Jul 14, 2021 - 09:45 AM
type_senate_hearing_abstract_blue_bkgd_logo

The Senate Judiciary Committee Subcommittee on Competition Policy, Antitrust, and Consumer Rights yesterday held a hearing on surging drug prices and anticompetitive conduct in the pharmaceutical industry.

Committee members and witnesses described how drug companies misuse patents and rebates to prevent competition and increase prices. 

“Drugs don’t work if people can’t afford them,” said David Mitchell, founder of Patients for Affordable Drugs and a cancer patient, noting that a drug for which he might be a candidate carries a list price of $419,500. 

Also testifying were representatives from the Washington Center for Equitable Growth, Mercatus Center at George Mason University, Pharmaceutical Research and Manufacturers of America, and biologics maker Fresenius Kabi.
 

Related News Articles

Headline
Report: Most hospitals, health plans posting machine-readable price transparency data
About 84% of hospitals had posted a machine-readable file containing rate information by the end of first-quarter 2023, up from 65% the previous quarter,…
Headline
CMS to test new models to lower drug costs 
The CMS Innovation Center will test three new models to see whether they lower high drug costs, the Centers for Medicare & Medicaid Services announced…
Headline
AHA expresses support for Drug-Price Transparency for Consumers Act
The AHA July 2 expressed support for the Drug-Price Transparency for Consumers Act of 2021 (S.2304).    “America’s hospitals and health systems are…
Headline
Report looks at cost to health system of brand name drug tactic
A new study demonstrates the cost to the U.S. health care system from an anti-competitive tactic known as “product hopping,” which involves a brand name drug…
Headline
California reports first cost data for prescription drugs
The California Office of Statewide Health Planning and Development recently released the nation’s first mandatory data on wholesale acquisition cost increases…
Blog
Flawed Report on Specialty Drug Spending Fails to Place Blame on Drug Companies
A recent report from UnitedHealth comparing specialty drug spending in hospitals and independent physician offices fails to account for critical differences…